1. Home
  2. Disease & Disorders
  3. Los Angeles, CA
  4. Pituitary Society

Pituitary Society

Pituitary Society is ranked #3 of 21 disease & disorders organizations in Los Angeles, CA, with an America's Best Score of 87 out of 100, based on its 2025 Form 990.

  • Los Angeles, CA
  • Tax-exempt since 2004
  • EIN: 22-3307141
ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
87OF 100 #3 of 21 in Los Angeles ranked disease & disorders organizations How this score is calculated

Organization summary

Pituitary Society is a 501(c)(3) organization, classified under Disease & Disorders (NTEE G43). Contributions are tax-deductible.

8700 Beverly Blvd 2051, Los Angeles, CA 90048-1804

Among the 28 scored disease & disorders organizations in Los Angeles, Pituitary Society holds 59.3 months of operating reserves (peer median 13.4 months), runs a typical yearly surplus of 42.0% (peers: surplus of 3.7%), and has grown spending 32.7% a year (peers: grown spending 9.7% a year).

In fiscal year 2025 it reported $753,709 in revenue and $483,415 in expenses, with contributions making up 92.1% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

Our mission is to provide scientists, clinicians and trainees with the most up-to-date, reliable research and education on the biology of the pituitary gland and the causes, diagnosis and treatment of pituitary gland related diseases, in order to improve patient care and to provide a uniquely international forum for professional growth and scientific exchange.

Largest programs · fiscal year 2025

  • Gropro conferencethe growth hormone (gh)/ prolactin (prl) family in biology & disease conference (gropro) was held August 11-15, 2024, in stirling, scotland. This conference used to be associated with federation of American societies for experimental biology (faseb) and before that with the gordon conferences. So, it has long history, over 2 decades. This iteration of the conference was held in as… Read more

    Gropro conferencethe growth hormone (gh)/ prolactin (prl) family in biology & disease conference (gropro) was held August 11-15, 2024, in stirling, scotland. This conference used to be associated with federation of American societies for experimental biology (faseb) and before that with the gordon conferences. So, it has long history, over 2 decades. This iteration of the conference was held in association with the Pituitary Society. This conference was held in europe for the first time with over 90 scientists, physicians, and trainees in attendance.the scientific theme of this conference is to improve our understanding of the regulation and action of gh and prl and their specific receptors as well as their role in disease promotion or prevention.

    $100,100 spent · 77.7% of program spending
  • Preceptorship course for fellows-in-trainingthis course, held in January 2025, was the seventh since its inception. The course was attended by approximately 225 fellows-in-training. Fellows were required to submit an interesting pituitary case to attend the course. Cases were reviewed by faculty and four-to-six were selected to be presented by the fellows during the case discussion. Faculty record… Read more

    Preceptorship course for fellows-in-trainingthis course, held in January 2025, was the seventh since its inception. The course was attended by approximately 225 fellows-in-training. Fellows were required to submit an interesting pituitary case to attend the course. Cases were reviewed by faculty and four-to-six were selected to be presented by the fellows during the case discussion. Faculty recorded presentations on all pituitary pathology were viewed by the fellows prior to the live webinars to allow for more interactive learning.over the last decade, many endocrinology fellowship programs reduced the training requirements from 3 years to 2 years to be eligible for board certification. In parallel, diabetes and obesity incidence and prevalence increased significantly, limiting clinical experiences on other rarer, nevertheless severe and potentially lethal diseases, such as pituitary disorders. Therefore, this course taught by leading international experts, addressed some of these issues by reviewing for trainees advancements in diagnosis and treatment of hypopituitarism, growth hormone deficiency, cushing's syndrome and acromegaly as well as management of pituitary disease in the post-covid era.

    $18,648 spent · 14.5% of program spending
  • Pituitary Society consensus guideline for pituitary incidentalomas (published guideline)within the constraints of limited evidence-based reports, this Pituitary Society consensus summarizes the epidemiology and natural history, diagnostic work-up, and treatment options for patients with pituitary incidentalomas. We distinguish between pituitary adenomas and other types of incidentalomas and partic… Read more

    Pituitary Society consensus guideline for pituitary incidentalomas (published guideline)within the constraints of limited evidence-based reports, this Pituitary Society consensus summarizes the epidemiology and natural history, diagnostic work-up, and treatment options for patients with pituitary incidentalomas. We distinguish between pituitary adenomas and other types of incidentalomas and particularly distinguish between microadenomas and macroadenomas given the lower likelihood of the latter to be a truly incidental finding.the guidelines were published in nature reviews endocrinology.

    $10,000 spent · 7.8% of program spending

Where each dollar went · fiscal year 2025

Of every dollar it spent, 27¢ went to programs, 73¢ to management and 0¢ to fundraising.

  • Programs $128,748
  • Management $354,667
  • Fundraising $0

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score87 / 100
Rank in Los Angeles#3 of 21
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves (reduced: more than 3 years of cash)59.3 mo; 67.8 mo in cash15.6 / 25
Financial balance (median margin)+42.0%19.7 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+32.7% / yr15 / 15
Track record22 years8.8 / 10
Debt load22.4% of assets7.5 / 10
Total86.6 → 87
Spending on programs
Not scored; America's Best needs 65%+
27%Below

Compared with Los Angeles peers

MeasureThis organizationPeer median
Operating reserves59.3 mo13.4 mo
Typical margin+42.0%+3.7%
Spending growth+32.7% / yr+9.7% / yr
Debt load22.4%2.4%

Peers: the 28 Los Angeles disease & disorders organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$753,709Fiscal year 20252022: $287,12920222023: $798,09520232024: $551,12920242025: $753,7092025
Expenses$483,415Fiscal year 20252022: $206,82720222023: $549,74920232024: $488,82220242025: $483,4152025
Total assets$3,079,505Fiscal year 20252022: $1,840,97520222023: $2,298,43220232024: $2,128,71720242025: $3,079,5052025
Total liabilities$689,239Fiscal year 20252022: $31,65620222023: $240,76720232024: $8,74520242025: $689,2392025
Fiscal year ending June 2025
Revenue$753,709
Expenses$483,415
Net income$270,294
Net assets$2,390,266

Notable sources of revenue

Percent of total revenue
Contributions$694,053
Program services$2,230
Investment income$56,433
Other (net)$993

Assets / debt

Total assets$3,079,505
Total liabilities$689,239
Net assets$2,390,266

Compensation

Not in our extract for this year.

Fiscal year ending June 2024
Revenue$551,129
Expenses$488,822
Net income$62,307
Net assets$2,119,972

Notable sources of revenue

Percent of total revenue
Contributions$413,854
Program services$66,725
Investment income$63,243
Other (net)$7,307

Assets / debt

Total assets$2,128,717
Total liabilities$8,745
Net assets$2,119,972

Compensation

Not in our extract for this year.

Fiscal year ending June 2023
Revenue$798,095
Expenses$549,749
Net income$248,346
Net assets$2,057,665

Notable sources of revenue

Percent of total revenue
Contributions$433,264
Program services$327,460
Investment income$27,475
Other (net)$9,896

Assets / debt

Total assets$2,298,432
Total liabilities$240,767
Net assets$2,057,665

Compensation

Officers and key employees$0
Share of expenses0.0%
Fiscal year ending June 2022
Revenue$287,129
Expenses$206,827
Net income$80,302
Net assets$1,809,319

Notable sources of revenue

Percent of total revenue
Contributions$22,450
Program services$262,450
Investment income$137
Other (net)$2,092

Assets / debt

Total assets$1,840,975
Total liabilities$31,656
Net assets$1,809,319

Compensation

Officers and key employees$0
Share of expenses0.0%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?